Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Teriflunomide: A Novel Oral Treatment for Relapsing Multiple Sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research A Comparative Study of Regulations of Cell and Gene Therapy in the US, EU, and India
The US and EU lead in cell and gene therapy regulations with more approvals and clinical trials, while India is in early stages with fewer approvals and expedited processes.
research Alopecia Areata: Time for Position Statement to Include New Systemic Therapeutic Advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research Artificial Hair: From the Dawn to Automatic Biofibre Hair Implant
Biofibre® hair implants are safe and effective for alopecia when proper procedures are followed, with high patient satisfaction.
Community Join
5 / 122 resultscommunity Mid 40s Fin only - 12 month update.
A user in their mid-40s shared a 12-month update on using finasteride for hair loss, showing significant improvement. They started seeing thicker hair and regrowth after 3 months, with no side effects noticed.
community Concerns about CosmeRNA safety mechanisms
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
community Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community HMI-115 start AGA phase 2 trial volunteer in China. The eligible volunteer should be age between 18 to 65, Norwood 3 vertex , 4 and 5. And agree to prevent pregnancy. The trial is leaded by the doctor in Beijing hospital.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.